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Recent studies suggest that secreted phospholipases A2 (sPLA2s) represent attractive potential tumour biomarkers and therapeutic
targets for various cancers. As a first step to address this issue in human colorectal cancer, we examined the expression of the full set
of sPLA2s in sporadic adenocarcinomas and normal matched mucosa from 21 patients by quantitative PCR and
immunohistochemistry. In normal colon, PLA2G2A and PLA2G12A were expressed at high levels, PLA2G2D, PLA2G5, PLA2G10
and PLA2G12B at moderate levels, and PLA2G1B, PLA2G2F and PLA2G3 at low levels. In adenocarcinomas from left and right colon,
the expression of PLA2G3 was increased by up to 40-fold, while that of PLA2G2D and PLA2G5 was decreased by up to 23- and
14-fold. The variations of expression for sPLA2-IID, sPLA2-III and sPLA2-V were confirmed at the protein level. The expression
pattern of these sPLA2s appeared to be linked respectively to the overexpression of interleukin-8, defensin a6, survivin and matrilysin,
and downregulation of SFRP-1 and RLPA-1, all these genes being associated to colon cancer. This original sPLA2 profile observed in
adenocarcinomas highlights the potential role of certain sPLA2s in colon cancer and suggests that sPLA2-III might be a good candidate
as a novel biomarker for both left and right colon cancers.
British Journal of Cancer (2008) 98, 587–595. doi:10.1038/sj.bjc.6604184 www.bjcancer.com
Published online 22 January 2008
& 2008 Cancer Research UK
Keywords: colon cancer; secreted phospholipase A2; gene expression; qPCR; immunohistochemistry; biomarker
                                               
Sporadic colorectal cancer is a major human health concern in
industrialised countries and is the third leading cause of mortality by
cancer. The accumulation of genetic alterations in several key genes
(APC, K-ras, DCC and p53) has been associated with tumour
development (Fearon and Vogelstein, 1990). In particular, the
activation of the Wnt/b-catenin/Tcf-4 pathway is known to play a
key role in colon tumorigenesis, leading to overexpression of a large
number of target genes, including c-myc, cyclin D1, MMP-7, ITF-2, Il-
8, gastrin, uPAR, cryptdin/defensin and EPR-1 genes (Kolligs et al,
2002; Levy et al, 2002). Moreover, the participation of tumour
modifier genes may also contribute to pathogenesis, providing a
basis to individual genetic predispositions, in addition to environ-
mental and diet influences (Wiesner et al, 2003; Yan et al,2 0 0 4 ;
Rakoff-Nahoum and Medzhitov, 2007). A comprehensive character-
isation of such tumour modifier genes must take into account the
stage of cancer and the location of the tumour within the large
intestine, that is, ‘right’ or ‘left’ colon. This information may lead to a
better understanding of the molecular events involved in colorectal
cancer, and may provide new therapeutic targets to improve patient
treatment outcomes (Williams et al, 2003; Barrier et al, 2005). It is
also of interest to investigate the expression of such genes to identify
new biomarkers of human colorectal cancers for early diagnosis and
prognosis (Williams et al, 2003; Barrier et al, 2005).
In humans, 10 secreted phospholipases A2 (sPLA2s) have been
described in the last decade, and the analysis of their functions in
physiological and pathophysiological conditions is under intense
investigation. Human sPLA2s have been classified into groups IB,
IIA, IID, IIE, IIF, III, V, X, XIIA and XIIB according to their
structural properties (Laye and Gill, 2003; Rouault et al, 2003;
Murakami et al, 2005; Cummings, 2007). Several of these proteins
have recently been proposed either as biomarkers of pathologies
(Smith et al, 2003; Mallat et al, 2005; Wootton et al, 2007) or as
therapeutic targets (Laye and Gill, 2003; Cummings, 2007;
Henderson et al, 2007). These enzymes have the capacity to
generate biologically active lipid mediators such as lysophos-
phatidic acid (LPA) and arachidonic acid (AA), which can be
further converted into prostaglandin E2 (PGE2). These lipid
mediators are known to be involved in cell proliferation, cell
migration, angiogenesis, and are likely to play a role in the
initiation and/or progression of colorectal cancer (Morioka et al,
2000; Krause and DuBois, 2001; Laye and Gill, 2003; Mills and
Moolenaar, 2003; Murakami et al, 2005). AA can also participate in
apoptosis by activating sphingomyelinases and ceramide produc-
tion (Dong et al, 2005; Ilsley et al, 2005).
Received 2 October 2007; revised 12 December 2007; accepted 12
December 2007; published online 22 January 2008
*Correspondence: Dr G Lambeau, Institut de Pharmacologie Mole ´culaire
et Cellulaire, CNRS-UNSA UMR6097, 660 route des Lucioles, Sophia
Antipolis, 06560 Valbonne, France; E-mail: lambeau@ipmc.cnrs.fr
British Journal of Cancer (2008) 98, 587–595
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sSecreted phospholipases A2 have been recently proposed as
targets for anticancer drugs (Laye and Gill, 2003; Cummings,
2007), and there is increasing evidence for their involvement in
various human cancers. Indeed, the expression levels of sPLA2-V
and sPLA2-X are modified in human lung cancer (Masuda et al,
2005b), and those of sPLA2-V and sPLA2-XIIA in human ovarian
cancer (Gorovetz et al, 2006). In particular, the overexpression of
human sPLA2-IIA in gastric adenocarcinoma was proposed to
be related to prolonged survival and less frequent metastasis
(Leung et al, 2002; Aggarwal et al, 2006). By contrast, sPLA2-IIA
overexpression has been associated to oncogenic effects in prostate
cancer (Sved et al, 2004) and is related to poor prognosis (Graff
et al, 2001). The polymorphism of the sPLA2-IIA gene, PLA2G2A,
is also associated to some phenotypic features of patients with
familial adenomatous polyposis (Yanaru-Fujisawa et al, 2007).
More recently, human sPLA2-XIIB was shown to be upregulated in
50% of patients with hepatitis C virus-associated hepatocellular
carcinoma (Smith et al, 2003). Finally, a protective role for
sPLA2-IIA against Apc
Min-induced intestinal tumours has been
established in mice (MacPhee et al, 1995; Cormier et al, 1997).
However, data on sPLA2 and human cancers are still sparse, and
often rely on only one or a few sPLA2s.
In this study, we have analysed the expression pattern of the full
set of sPLA2s in tumour vs normal matched mucosa from patients
with adenocarcinomas located in the left and right colon. Variation
in the expression of a number of other genes associated with colon
tumorigenesis and/or inflammation was also examined to establish
possible gene coregulations. Our data provide the first compre-
hensive analysis of the expression pattern of all sPLA2s in normal
human colon mucosa as well as adenocarcinomas. These data
further support the fact that several sPLA2s may contribute to the
initiation, progression or modulation of colon tumorigenesis, and
may provide new potential tumour markers for this disease.
MATERIALS AND METHODS
Human tissues and RNA isolation
Fourteen colon adenocarcinoma specimens from the left colon
(descending part of the colon) and seven colon adenocarcinoma
specimens from the right colon (ascending part of the colon) were
obtained from surgical resections according to the French and
American institutional guidelines. No specimen was from rectum.
The patients did not receive chemotherapy or radiotherapy prior
to surgery. The specimens were from 42- to 85-year-old patients
(median age: 71 years), 14 men and 7 women. Samples were well
(3 out of 21), moderately (14 out of 21) or poorly (4 out of 21)
differentiated sporadic adenocarcinomas, with pTNM classification
ranging pT2–4 N0–2 M0–1. Neither adenoma nor Duke’D
adenocarcinoma was examined in this study. All samples had an
expression of hMLH1 and hMSH2 unchanged as evaluated by
immunohistochemistry and quantitative PCR (qPCR) (data not
shown). Tissues from the non-necrotic part of the tumour and from
distant normal mucosa were snap frozen in liquid nitrogen and
stored at  801C. Each tissue sample (20–100mg) was mixed with
700ml of lysis buffer plus b-mercaptoethanol (nucleospin RNA II kit;
Macherey-Nagel, Hoerdt, France) in a green-cap tube containing
Lysing Matrix D (Q-BIOgene, Illkrich, France), and tissue disruption
was achieved with the fast prep instrument (FP220A; Q-BIOgene).
Total RNA was then isolated using the nucleospin RNA II kit,
including DNase treatment. RNA concentration was determined by
OD260 and RNA quality was evaluated by analysis on an Agilent
Bioanalyzer (Agilent Technologies, Les Ulis, France).
Quantitative PCR
First-strand cDNA was synthesised from 5mg of total RNA using
100U of MMLV reverse transcriptase (#M170A; Promega,
Charbonnie `res-les bains, France) in a final volume of 50ml with
500ng of random primers (#C118A; Promega). Quantitative PCR
was carried out in 96-well ABgene plates using the GENEAMP 5700
sequence Detection System apparatus (Applied Biosystems,
Courtaboeuf, France) with the qPCR Master Mix Plus for SYBR
s
Green I (Eurogentec, Angers, France). All reactions were
performed in a total volume of 16ml and contained 50ng of
reverse transcribed RNA (based on the initial RNA concentration)
and 250nM of each primer set. The primer sets were designed
using the Primer Express program from Applied Biosystems for
the following human genes: PLA2G2A (NM_000300), sPLA2-IID
gene (PLA2G2D) (NM_012400), sPLA2-IIE gene (PLA2G2E)
(NM_0145891), sPLA2-IIF gene (PLA2G2F) (NM_022819),
sPLA2-III gene (PLA2G3) (NM_015715), sPLA2-V gene (PLA2G5)
(NM_000929), sPLA2-X gene (PLA2G10) (NM_003561),
sPLA2-XIIA gene (PLA2G12A) (BC_017218), sPLA2-XIIB gene
(PLA2G12B) (NM_032562), iPLA2-VIB gene (PLA2G6)
(NM_003560), ptgs1 (BC_029840), COX-2 gene (ptgs2)
(NM_000963), ptges1 (NM_004878), ptges2 (NM_198797), Il-1a
(NM_000575), Il-6 (NM_000600), Il-10 (NM_57627), PPARg
(NM_138712), PPARd (NM_006238), u-PA (NM_002658), u-PAR
(NM_002659), IL-8 (NM_000584), EPR-1 (NM_002219), MMP-7
(NM_002423), SFRP-1 (NM_003012), PLA2R1 (NM_007366),
TNF-a (NM_000594), MMP-9 (NM_004994), MSH2 (NM_000251),
MLH1 (NM_000249). Most primer sets were designed to span an
intron in order to avoid amplification from potential traces of
genomic DNA in the total RNA preparations. Only the primer sets
for MLH1, uPAR, EPR-1, MMP-7 and bcl-2 genes were not
spanning an intron. For primer sets spanning an intron, we
checked that no amplification signal was obtained using human
genomic DNA as template in the qPCR (data not shown). The
sequences of the designed primer sets are available on request.
We used Qiagen commercial primer sets for cPLA2-IVA gene
(PLA2G4A) (ref. QT00085813) and sPLA2-IB gene (PLA2G1B) (ref.
QT00000637). We used published primer sets for RLPA-1 and
RLPA-2 genes (Shida et al, 2004) and HD-6 gene (Andreu et al,
2005). The efficiency and specificity of each primer sets were
validated using either serial dilutions of cloned human sPLA2
cDNAs or mixed human tissue cDNA for the other genes.
Moreover, when enough total RNA was collected, negative controls
without added reverse transcriptase were performed. Thermal
cycling was performed at 951C for 10min, followed by 40 cycles
comprising each a denaturation step at 951C for 15s, and an
annealing/extension step at 601C for 1min. Amplification of the
appropriate product was verified by analysing the dissociation
curve that was obtained after PCR with the following steps: 15s at
951C, 20s at 601C, and then a slow ramp of 20min from 60 to 951C.
The abundance of the mRNA target was calculated relative to the
expression of the reference gene TOP1 and is expressed as 2DCt,
where DCt¼Ct (gene of interest) Ct (TOP1). The choice of TOP1
as a reference gene was determined using a Human GeNorm kit
(PrimerDesign Ltd, Southampton, UK), allowing the determination
of the best reference gene among 12 widely used reference genes.
The data were also validated using GAPDH as a reference gene
(data not shown). When the relative level of expression was plotted
for normal mucosa (n) (Figure 1), we used the formula 220 DCtðnÞ,
with DCt¼Ct(n)gene Ct(n)TOP1. The Ct(n) values for TOP1 were
typically around 20. When the expression of each gene in normal
mucosa vs tumours (Figures 2–4) was plotted, the comparative Ct
method (detailed in the ABI Prism 7700 Sequence Detection
System User Bulletin no. 2) was used to determine the relative
quantities of mRNA, and we changed the sign in order to get the
lowest level of expression at the bottom and the highest level
of expression at the top of the y axis, that is,  DCt¼ (Ct gene of
interest Ct TOP1). When the expression of each gene was
compared between the tumour (t) and the matched normal
mucosa (n), the decrease or increase factor f in the tumour vs the
normal mucosa (Figure 5A and B) was calculated with the formula
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sf¼ 2IDCtðnÞ DCtðtÞI 1, with DCt(n)¼Ct(n)gene Ct(n)TOP1,
DCt(t)¼Ct(t)gene Ct(t)TOP1, and I the absolute value of the
term DCt(n) DCt(t).
Immunohistochemistry
All experiments were performed using paraffin-embedded tissues
from the same patients as those used for the qPCR experiments.
The expression of sPLA2-IID, sPLA2-III, sPLA2-V and COX-2
proteins was analysed in tumours and normal matched tissues
from three to four patients. Consecutive 4-mm tissue sections were
deparaffinised in xylene and rehydrated in graded alcohol
dilutions. Immunolabelling was performed using avidin–biotin–
peroxidase technique (Vectastain ABC kit; Vector, Burlingame,
CA, USA). Before immunostaining, endogenous peroxidase activity
was inhibited with 0.1% hydrogen peroxide in methanol for
30min. Colour development was achieved with 3-amino-9-ethyl-
carbazole, and sections were finally counterstained with haema-
toxylin. Specific rabbit polyclonal antibodies against recombinant
human sPLA2-IID, sPLA2-III and sPLA2-V were produced as
described (Haas et al, 2005), and used at working dilutions of
1/300, 1/250 and 1/100, respectively. All anti-sPLA2 antibodies were
tested for specificity towards the various sPLA2s and were shown
to be highly specific for each human sPLA2 (Haas et al, 2005).
Negative controls were performed by omission of the primary
antibody. To further check for the specificity of labelling with
sPLA2-IID-, sPLA2-III- and sPLA2-V-specific antibodies, competi-
tion experiments were performed in which the antibody was
preincubated with the corresponding purified recombinant sPLA2
used for immunisation, prior to covering the tissue slides. The
competition was performed by preincubating the relevant antibody
solution with 200nM of human recombinant sPLA2-III or 100nM of
human recombinant sPLA2-IID and sPLA2-V for 1h at room
temperature. Purified recombinant proteins were obtained as
described (Rouault et al, 2007). Human COX-2 antibodies were
from Cayman (Montigny-le Bretonneux, France) (ref. 160112,
working dilution 1/500), human MLH1 antibodies were from BD
Pharmingen (Le Pont-de-Claix, France) (clone G168-178, working
dilution 1/100), and human MSH2 antibodies were from
Calbiochem (Darmstadt, Germany) (clone FE-11, working dilution
1/125).
Statistics
We determined that the sample data from left and right colons
followed a Gaussian distribution using the D’agostino–Pearson
normality test. Normal mucosa and tumour paired data for each
gene were analysed using the Bonferroni test, and statistical
significances were represented by *Po0.05, **Po0.01 and
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Figure 2 Expression level of sPLA2 genes in human adenocarcinomas and normal matched mucosa. The expression level of sPLA2 genes and of the
M-type sPLA2 receptor (PLA2R1) was measured in adenocarcinomas and normal matched mucosa for the 14 left-sided samples. The data were obtained
after normalisation with TOP1 used as reference gene and using the formula  DCt¼Ct gene of interest Ct TOP1. N, normal tissues; T, tumour tissues.
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Figure 1 Expression level of sPLA2 genes in human colon normal
mucosa. The relative averaged expression level of all sPLA2 genes and the
two reference genes used in this study (TOP1 and GAPDH) is shown for the
14 samples from left colon and the 7 samples from right colon. Arbitrary
units are used (see Materials and Methods).
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s***Po0.001. We looked for correlation between all genes
examined in this study by using the Mev3.1 software and
hierarchical clustering to analyse different linkages to cluster
genes and samples. Euclidean distance was used to calculate the
distance between two genes.
RESULTS
Expression levels of sPLA2 genes in normal human colon
mucosa
We first looked at the mRNA levels for the different sPLA2 genes in
normal mucosa and compared their relative expression levels. Our
data show dramatic differences in the relative expression of sPLA2.
The lowest gene expression level was found for PLA2G3, and the
highest gene expression level was found for PLA2G2A (Figure 1).
The level of PLA2G2A expression was particularly high. It is above
that of TOP1 and almost reaches that of GAPDH, which are both
used as reference genes and are known to be highly expressed in
many tissues, including colon. By contrast, the expression of
PLA2G3 was generally very low, in fact below the limit of detection
in many samples (Figure 1). The expression levels of PLA2G2F
and PLA2G1B were also low, while that of other sPLA2 genes were
moderate. The expression of PLA2G2E was not detectable (data not
shown). We also compared the expression levels in normal mucosa
of left and right colon. A significant difference in gene expression
levels was seen for PLA2G2F, PLA2G1B, PLA2G12B and PLA2G10
(respectively 30-, 13-, 24- and 40-fold lower expression in right-
sided normal mucosa than in left-sided normal mucosa). No or
minor differences were observed in gene expression for PLA2G2A,
PLA2G2D, PLA2G3, PLA2G5 and PLA2G12A between right- and
left-sided normal mucosa (Figure 1).
Expression levels of sPLA2 genes in left and right colon
adenocarcinomas vs normal human colon mucosa
We next compared sPLA2 gene expression in adenocarcinomas vs
normal mucosa. The raw data for samples from the left colon are
shown in Figure 2. The fold-increase or fold-decrease in the
expression of each gene in adenocarcinomas vs normal mucosa
is represented in Figure 3. Interestingly, we observed a 40-fold
increase in PLA2G3 expression in the adenocarcinomas. In
contrast, we found 23- and 14-fold decreases for PLA2G2D and
PLA2G5, respectively. Similar data were obtained for samples from
the right colon, with a 22-fold increased expression in tumour vs
normal mucosa for PLA2G3, and 10- and 44-fold reduced
expression for PLA2G2D and PLA2G5, respectively (Figure 4).
No variation in expression between the tumours and normal
mucosa was observed for PLA2G1B, PLA2G2A, PLA2G2F,
PLA2G10, PLA2G12A and PLA2G12B and for the M-type sPLA2
receptor (PLA2R1) (Figures 3 and 4). The expression of PLA2G2E
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Figure 3 Expression level of sPLA2, tumour-related and inflammation-
related genes in human left colon adenocarcinomas. After normalisation
with the TOP1 reference gene, the expression level for each gene in the
tumour was compared to that in the normal matched mucosa. The zero
value indicates no variation, a positive value indicates an increased
expression level in tumour vs normal tissue and a negative value indicates
a decreased expression level in tumour vs normal tissue (see Materials and
Methods). The incidence of variation in the different samples is indicated.
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Figure 4 Expression level of sPLA2, tumour-related and inflammation-
related genes in human right colon adenocarcinomas. Same legend as
Figure 3.
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shown).
Expression levels of genes involved in inflammation and
tumorigenesis in left and right colon adenocarcinomas vs
normal human colon mucosa
Since sPLA2s may exert a coordinate action with other genes in
tumorigenesis and associated inflammation, we also examined
the expression of a panel of genes known to be involved in
inflammation and colorectal tumorigenesis (Figures 3 and 4).
In left colon samples, we did not observe any differences in
expression levels between adenocarcinomas and normal mucosa
for most of the inflammation-related genes examined in this study,
that is, ptgs2, ptges1, ptges2, TNF-a, Il-1a, Il-6, Il-10, PPARg,
PPARd, MMP-9 and PLA2G6. Only a slight decrease in the
expression of ptgs1 and PLA2G4A was observed. With the
exception of ptges2 and Il-1a, we found that the inflammation-
related genes were already expressed at high levels in the normal
mucosa.
We also looked at the expression of urokinase plasminogen
activator (u-PA) and its receptor (u-PAR) that play a role in cell
adhesion and cell migration, and are involved in late stages of
tumour development, contributing to tumour cell invasion and
metastatic spread (Terada et al, 2005). No changes were observed
in u-PA and u-PAR gene expression levels.
RLPA-1 and RLPA-2 genes code for two distinct LPA receptors
(Mills and Moolenaar, 2003). While the expression of RLPA-2 did
not change, that of RLPA-1 was decreased by 20-fold in tumour vs
normal matched mucosa.
IL-8, EPR-1, HD-6 and MMP-7 are target genes of the Wnt/b-cat/
tcf-4 pathway (Kolligs et al, 2002; Levy et al, 2002; Wheatley and
McNeish, 2005). Interestingly, a marked increase in expression was
found for Il-8, HD-6 and MMP-7 expression in the tumours (8-, 22-
and 70-fold, respectively). The level of EPR-1 was not changed.
SFRP-1 codes for an antagonist of the Wnt pathway, which binds to
the frizzled receptor and blocks frizzled–Wnt interaction (Suzuki
et al, 2004). Our results show a dramatic 130-fold decrease in the
expression of SFRP-1 in the tumour.
Similar data were obtained for most genes in the right-sided
samples (Figure 4). Indeed, no variation in expression was
observed for most inflammatory-related genes, while a dramatic
increase (280-fold) and a strong decrease (125-fold) were found for
MMP-7 and SFRP-1, respectively. However, in contrast to left-sided
samples, we observed no variation in HD-6 and Il-8 expression
levels and a strong increase (45-fold) in EPR-1 expression.
Incidence and coregulation of studied genes
We first looked at the incidence of the above variations, that is,
the number of samples showing an increase or decrease in the
expression level of a particular gene within the 21 patients used in
this study (Figures 3–5). The increase in PLA2G3 expression
showed a high incidence (12 out of 14 for left-sided samples and 5
out of 7 for right-sided samples), which was similar to that of
MMP-7 gene overexpression (10 out of 14 for left-sided samples
and 6 out of 7 for right-sided samples). The incidence for the
overexpression of HD-6 and Il-8 was lower, since these two genes
were not significantly upregulated in right-sided samples. The
decrease in PLA2G2D and PLA2G5 expression also showed a high
incidence (12 out of 14 and 5 out of 7; and 11 out of 14 and 5 out of
7, respectively), which was similar to that of RLPA-1 and SFRP-1
gene expression (13 out of 14 and 6 out of 7; and 14 out of 14 and 7
out of 7, respectively). We did not observe any difference between
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expression of PLA2G3, PLA2G2D and PLA2G5 (data not shown).
Euclidean distance is commonly used to evaluate linkages in the
expression of different genes. We used this method to point out
linkages between the variations in expression level of the most
relevant genes. In left-sided adenocarcinomas (Figure 5A), a first
cluster (cluster I) of upregulated genes was observed containing
PLA2G3 and several genes related to colon cancer such as HD-6,
MMP-7 and Il-8. A second cluster (cluster II) of several
downregulated genes, including SFRP-1, PLA2G2D, RLPA-1,
PLA2G5, PLA2G4A and ptgs1, was observed. These two clusters
appeared most likely to discriminate adenocarcinomas from
normal tissues. Remarkably, there are 3 sPLA2 genes out of 11
genes in these two clusters. The other genes did not show any
linkage with colon tumorigenesis, since their expression levels
were up- or downregulated or not changed among the different
patients. When looking at right-sided samples (Figure 5B), similar
patterns were observed even though the number of patients was
lower.
Protein expression levels of sPLA2-IID, sPLA2-III and
sPLA2-V in colon adenocarcinomas and normal matched
mucosa
To confirm that the variation of expression for PLA2G2D, PLA2G3
and PLA2G5 is also observed at the protein level, immunohisto-
chemical analyses were performed on tissue sections from the
same patients as those used for qPCR. For each sPLA2 protein
analysed, tissue sections from three or four patients showing a
significant increase or decrease of sPLA2 expression were selected
and immunostained (Figure 6). The labelling for sPLA2-IID and
sPLA2-V was markedly decreased in tumour cells compared to the
normal matched epithelium, in accordance with the qPCR data. By
contrast, the labelling for sPLA2-III was absent or very low in the
normal epithelium, with a significant increase in tumour tissue.
The absence of labelling in competition experiments (data not
shown) or when the primary antibody was omitted (Figure 6)
demonstrated that the signals observed for the three sPLA2
proteins were specific. In addition, immunohistochemical analysis
of COX-2 showed a more intense protein expression in tumours
than in normal mucosa in a subset of patients (data not shown).
DISCUSSION
Several lines of evidence have been accumulated during the past
decade to support the role of sPLA2s in cancer pathogenesis. Their
role in human cancer, however, has not been clarified. As a first
step towards addressing this issue, we have analysed the
expression patterns of the full set of human sPLA2s in colorectal
cancer tissue samples and normal matched mucosa. Our results
indicate that (i) several sPLA2s, including sPLA2-IIA, sPLA2-X and
sPLA2-XIIA, are highly expressed in both normal and tumour
colon tissues; (ii) the expression levels of sPLA2-III, sPLA2-IID and
sPLA2-V are dramatically altered in adenocarcinomas at both
mRNA and protein levels; and (iii) their mRNA profiles are part of
gene expression clusters with other genes associated with
inflammation and cancer. Together, our data are further suggestive
of a role of these sPLA2s in colorectal cancer and open the
possibility that sPLA2s, in particular sPLA2-III, may provide novel
cancer biomarkers.
sPLA2 gene expression levels in colon adenocarcinomas
and normal human colon
Colon adenocarcinomas analysed in this study are likely cancers
without high microsatellite instability. Indeed, we used immuno-
histochemical analysis as a reliable method for screening DNA
mismatch repair defects (Lindor et al, 2002), and found that the
expression of hMLH1 and hMSH2 was unchanged. Furthermore,
we analysed the normal mucosa and the tumour tissues from the
right and left colon separately because of their distinct gene
expression patterns (Glebov et al, 2003; Birkenkamp-Demtroder
et al, 2005). We observed similar levels of expression for most
sPLA2s in left and right normal mucosa, with PLA2G2A having a
high expression level, PLA2G3 being not detectable in most
samples and the other sPLA2 genes showing intermediate levels of
expression (Figure 1). Interestingly, we observed marked altera-
tions in the expression levels of PLA2G2D, PLA2G5 and PLA2G3 in
colon adenocarcinomas. In contrast, there was no difference in
the expression levels of the other sPLA2 genes (Figures 2–4). The
absence of tumour-related alterations in the gene expression of
PLA2G2A and PLA2G10 in human sporadic colon cancer tissues is
consistent with earlier studies (Dimberg et al, 1998; Osterstrom
et al, 2002; Murakami et al, 2005). These data obtained in humans
differ from those obtained in mice, which showed an increased
expression of PLA2G2A and no variation in PLA2G5 expression in
tumours from azoxymethane-treated mice (Ilsley et al, 2005).
Normal mucosa
IID
VV
III
Negative 
control
III
IID
Tumour
Figure 6 Secreted phospholipase A2 immunolabelling in representative
colon adenocarcinomas and normal matched mucosa. For sPLA2-IID and
sPLA2-V expression, a strong staining in the surface epithelium of the
normal mucosa was observed, contrasting with the weak or absent staining
observed in tumour cells. For sPLA2-III expression, a very faint staining was
observed in normal epithelial cells, contrasting with the moderate to strong
staining observed in tumour cells. For each sPLA2, a representative
immunolabelling from 1 patient out of 3–4 patients analysed is shown. As
shown in the bottom picture, no staining is observed when the primary
antibody is omitted. Scale bar is 100mm.
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sExpression level of genes involved in inflammation and
tumorigenesis in colon adenocarcinomas and normal
human colon
No significant changes between adenocarcinomas and normal
colon were observed for most inflammation-related genes. It
should be noted that many of these genes were expressed at high
levels within the normal mucosa, in particular, MMP-9, PLA2G6
and ptgs2. A recent study by Chen et al (2004) has also shown high
mRNA expression levels of several inflammation-related genes in
normal-appearing colon mucosa of patients with colon cancer.
Therefore, our data would suggest a possible pre-existing
inflammatory condition within the normal mucosa distant from
the tumours, and likely explain the absence of increased
expression in adenocarcinomas vs normal mucosa for several
inflammation-related genes. The slight decrease in ptgs1 (the COX-
1 gene) appeared in agreement with that observed in colon
adenocarcinomas of stage III (Duke’s C) patients (Church et al,
2004). The COX-1 protein is considered to exert dual opposing
effects in cancer, acting as either a tumour suppressor or a tumour
initiator (Chulada et al, 2000). The slight decrease in PLA2G4A
expression that we observed may be related to the dual opposing
effects of cPLA2-IVA in cancer, that is, proliferative effects via
metabolism of AA into eicosanoids, such as PGE2, and anti-
proliferative effects via AA-dependent ceramide production
leading to apoptosis (Ilsley et al, 2005). The absence of increase
in ptgs2 (the COX-2 gene) levels in our set of patients is in
accordance with two recent qPCR studies also performed on
patients with colon cancer (Church et al, 2004; Gustafsson et al,
2007), and may be related to the inflammatory status of the normal
mucosa discussed above. The fact that we did not observe an
increase of COX-2 at the mRNA level, while we detected an
overexpression at the protein level by immunohistochemistry as
previously reported (Wendum et al, 2003), is in line with the post-
transcriptional regulation of COX-2 expression (Dixon et al, 2003).
Therefore, mRNA and protein levels of COX-2 may not be closely
linked, as recently proposed in colon cancer tissues (Gustafsson
et al, 2007) and colon cancer cells (Dixon et al, 2003).
Downregulation of sPLA2-IID and sPLA2-V expression in
human colon adenocarcinomas
A marked decrease in the expression level of PLA2G2D and PLA2G5
was observed in both left- and right-sided adenocarcinomas
(Figures 2–4). These variations were also observed at the protein
level by immunohistochemical analyses. Indeed, sPLA2-IID and
sPLA2-V were found to be present in epithelial cells of normal
mucosa, and their expression was markedly reduced in tumours
(Figure 6). The decreased expression of sPLA2-IID and sPLA2-V in
tumours may suggest a protective role of these sPLA2s, as it has
been proposed for sPLA2-IIA in mice (MacPhee et al, 1995; Cormier
et al, 1997). A similar decrease in expression of sPLA2-IID and
sPLA2-V was also described in gastric tissues with signet-ring cell
carcinoma (Masuda et al, 2005a). Interestingly, the PLA2G2A,
PLA2G2C, PLA2G2D, PLA2G2E, PLA2G2F and PLA2G5 genes reside
within the same region of human chromosome 1 at p35–36.1
(Valentin et al, 2000), a region frequently altered in colorectal
cancer (Spirio et al, 1996). The decreased expression for PLA2G2D
and PLA2G5 appears to be linked (cluster II, Figure 5) to that
observed for PLA2G4A, ptgs1, SFRP-1 and RLPA-1, which have been
proposed as tumour suppressor genes in colon cancer (Chulada
et al, 2000; Shida et al,2 0 0 4 ;S u z u k iet al,2 0 0 4 ;D o n get al, 2005).
Upregulation of PLA2G3 and Wnt target genes in human
colon adenocarcinomas
A marked increase in sPLA2-III expression level was observed in
both left- and right-sided adenocarcinomas, a finding that was
confirmed by immunohistochemical analysis. No or very weak
sPLA2-III expression was observed in normal epithelial cells, but a
robust expression was observed in tumours (Figure 6). Our
findings are consistent with the recent observation that sPLA2-III
can trigger the proliferation of human colon cancer cells in vitro
(Murakami et al, 2005). Parallel to the increase in PLA2G3 gene
expression level, we observed an increase in the expression level of
four target genes of the Wnt/b-cat/Tcf-4 pathway: Il-8 (Levy et al,
2002), HD-6 (also called defensin a6) (Kolligs et al, 2002), MMP-7
(also called matrilysin) (Nelson et al, 2000) and EPR-1 (also called
survivin) (Kolligs et al, 2002), as well as a concomitant dramatic
decrease in SFRP-1 gene expression level. Therefore, our data are
consistent with the activation of the Wnt/b-cat/Tcf-4 pathway in
the development of colon adenocarcinomas. It will be of interest to
determine whether the expression of PLA2G3 is related to the
activation of the Wnt/b-cat/Tcf-4 pathway, as already suggested for
PLA2G2A in gastric cancer (Aggarwal et al, 2006).
Our data further support the role of LPA in the pathogenesis of
colon cancer. LPA exerts its effects through at least three different
receptors: RLPA-1, RLPA-2 and RLPA-3 (Mills and Moolenaar,
2003). It has been demonstrated that the Wnt/b-cat/Tcf-4 pathway
is involved in the proliferative effects of LPA through binding to
RLPA-2 (Yang et al, 2005). We observed a decreased expression
of RLPA-1 and a sustained expression of RLPA-2, which is in
agreement with the predominant expression of RLPA-2 in
adenocarcinomas (Shida et al, 2004). Whether sPLA2-III plays a
role in the production of LPA, which in turn activates RLPA-2,
remains to be established.
The sPLA2-III as a novel potential biomarker of human
colon cancer
Because of their upregulation during colorectal carcinogenesis,
Wnt target genes and their associated products have been
examined for their potential use as biomarkers. The level of Il-8
protein was found to be increased in colorectal cancer patients
(Terada et al, 2005). A significant increase in the level of defensin
a6 has also been found in patients with colon cancer (Nam et al,
2005). Although Il-8 and defensin a6 levels have been recently
proposed as markers of human colorectal cancer (Nam et al, 2005;
Terada et al, 2005), our data show that they would detect only left-
sided adenocarcinomas (Figures 3–5). In contrast, the increased
expression of sPLA2-III was observed in both left and right colon
adenocarcinomas, indicating that the analysis of sPLA2-III levels
would detect cancers located in both left and right colon. MMP-7 is
a matrix metalloprotease that has been associated with tumour
invasion and metastasis (Nelson et al, 2000). We found that the
expression pattern of PLA2G3 was more similar to that of MMP-7,
which was also increased in both left and right colon adenocarci-
nomas (Figures 3–5).
In conclusion, this work is the first comprehensive analysis of
the expression pattern of the full set of sPLA2s in human colon
cancer. The distinct expression pattern observed for sPLA2 genes
suggests that mRNA profiling of the full set of human sPLA2s may
be useful to detect colon tumours either by analysing their
expression pattern in tumours (Barrier et al, 2005), in circulating
blood cells (Burczynski et al, 2005) or directly in serum on
circulating mRNA, as recently proposed for other genes (Li et al,
2006). Moreover, we have observed a dramatic increase in sPLA2-
III expression in both left- and right-sided adenocarcinomas,
suggesting that sPLA2-III may represent a novel broad molecular
biomarker of colon cancer. It will be of interest to determine
whether the expression level of sPLA2-III also increases at earlier
stages of tumorigenesis, including adenomas. It will also be useful
to detect the sPLA2-III protein in human colon biopsies, stools or
serum using the recently time-resolved fluoroimmunoassays
developed for the different human sPLA2s (Nevalainen et al, 2005).
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